Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Influenza Medications Market

Influenza Medications Market Trends

Report ID: GMI8695
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Influenza Medications Market Trends

With the rising number of influenza cases there is a greater demand for medications to treat and prevent the illness, driving growth in the market.
There has been growing awareness among both healthcare professionals and the public about the importance of early detection and treatment of influenza. Additionally, the availability of effective treatments, such as antiviral drugs, has led to greater adoption of influenza medications among healthcare professionals and patients. As a result, more individuals are seeking treatment for influenza symptoms, leading to increased growth of market.
Furthermore, pharmaceutical companies and research institutions are actively engaged in research and development activities aimed at discovering and developing new influenza drugs. These efforts are driven by the need to address challenges such as antiviral resistance, limited treatment options, and the potential for future influenza pandemics, further fostering the market expansion.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Influenza medications market size was USD 942.6 million in 2023 and is expected to register 2.9% CAGR from 2024-2032 owing to the increasing prevalence of influenza worldwide.

The antiviral drugs segment recorded 55.2% share in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to being considered as the primary treatment for influenza infections.

North America influenza medications industry is expected to register 2.7% CAGR from 2024-2032 due to a significant burden of influenza infections annually, with millions of cases reported each year in the region.

AstraZeneca plc, BioCryst Pharmaceuticals, Inc., Daiichi Sankyo Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Lupin, NATCO Pharma Limited, Novartis AG, Sanofi, and Teva Pharmaceutical Industries Ltd., are some of the major influenza medications companies worldwide.